Lucid Diagnostics Inc. (LUCD)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1799011 · fiscal year ends in Dec
Closing price $0.41 on 30 Oct 2026; 52-week range $0.32 to $1.47.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $5.4M
- Revenue growth
- 24.9%
- Net income, last twelve months
- -$52.3M
- Earnings per share
- -$0.47
- Operating margin
- -930.8%
- Net margin
- -959.8%
- Return on equity
- -478.3%
- Market value
- $77.3M
- Cash
- $33.4M
- Debt
- $23.5M
- Debt to equity
- 2.15
- Shares outstanding
- 190.8M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $4.7M | -$49.6M | -$58.0M | -$0.69 | -$46.7M | 10-K filed 25 Mar 2026 |
| FY2024 | 31 Dec 2024 | $4.3M | -$46.1M | -$45.5M | -$1.05 | -$44.4M | 10-K filed 24 Mar 2025 |
| FY2023 | 31 Dec 2023 | $2.4M | -$48.5M | -$52.7M | -$1.26 | – | 10-K filed 25 Mar 2024 |
| FY2022 | 31 Dec 2022 | $377.0K | -$56.2M | -$56.2M | -$1.55 | -$32.9M | 10-K filed 25 Mar 2024 |
| FY2021 | 31 Dec 2021 | $500.0K | -$27.4M | -$28.1M | -$1.51 | -$18.5M | 10-K filed 6 Apr 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $1.5M | -$11.7M | -$0.08 |
| Q1 FY2026 | 31 Mar 2026 | $1.3M | -$13.9M | -$0.17 |
| Q4 FY2025 | 31 Dec 2025 | $1.5M | -$16.3M | -$0.12 |
| Q3 FY2025 | 30 Sep 2025 | $1.2M | -$10.4M | -$0.10 |
| Q2 FY2025 | 30 Jun 2025 | $1.2M | -$4.4M | -$0.08 |
| Q1 FY2025 | 31 Mar 2025 | $828.0K | -$26.9M | -$0.52 |
| Q4 FY2024 | 31 Dec 2024 | $1.2M | -$11.5M | -$0.20 |
| Q3 FY2024 | 30 Sep 2024 | $1.2M | -$12.4M | -$0.25 |
Company events
The newest 8-K filings of 72 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 22 Oct 2026 | 8-K | Share sale, Shareholder rights change, Bylaws or fiscal year change | 3.02, 3.03, 5.03, 9.01 |
| 16 Oct 2026 | 8-K | Delisting notice | 3.01, 9.01 |
| 22 Sep 2026 | 8-K | Investor update | 7.01, 9.01 |
| 13 Aug 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 24 Jun 2026 | 8-K | Shareholder vote, Bylaws or fiscal year change | 5.03, 5.07, 9.01 |
| 14 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 24 Apr 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 23 Apr 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 26 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 12 Nov 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 25 Sep 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 11 Sep 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 176 held.
| Filed | Form | Period |
|---|---|---|
| 22 Oct 2026 | 8-K | 21 Oct 2026 |
| 16 Oct 2026 | 8-K | 12 Oct 2026 |
| 22 Sep 2026 | 8-K | 22 Sep 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 12 Aug 2026 | 10-Q | 30 Jun 2026 |
| 24 Jun 2026 | 8-K | 24 Jun 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
| 13 May 2026 | 10-Q | 31 Mar 2026 |
| 30 Apr 2026 | DEFA14A | – |
| 30 Apr 2026 | ARS | 31 Dec 2025 |
| 30 Apr 2026 | DEF 14A | 30 Apr 2026 |
| 24 Apr 2026 | 8-K | 24 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 20 May 2026 | Matheis Dennis, Director | Purchase | 245,000 | $1.00 | $245.3K | 1,033,443 | 21 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 9 Feb 2026 | PAVmed Inc. | 13D amended | 27.5% | 38.8M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 13.6M | +1.3% | 5.81 |
| 30 Sep 2026 | 13.5M | +4.87% | 10.32 |
| 15 Sep 2026 | 12.8M | +7.91% | 12.48 |
| 31 Aug 2026 | 11.9M | -7.33% | 14.52 |
| 14 Aug 2026 | 12.8M | +5.77% | 12.28 |
| 31 Jul 2026 | 12.1M | +11.34% | 8.29 |
| 15 Jul 2026 | 10.9M | +15.61% | 7.02 |
| 30 Jun 2026 | 9.4M | +26.84% | 3.64 |
Funds that hold it
From each fund's latest Form 13F.
125 funds held it at 30 Jun 2026: 83 added and 12 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Alyeska Investment Group, L.P. | 8,856,844 | $9.5M | +8,856,844 |
| BlackRock, Inc. | 8,373,117 | $9.0M | +3,734,874 |
| Vanguard Capital Management LLC | 6,556,344 | $7.0M | +2,401,574 |
| Two Seas Capital LP | 6,000,000 | $6.4M | +3,000,000 |
| Masters Capital Management LLC | 4,000,000 | $4.3M | 0 |
| Aberdeen Group plc | 3,822,997 | $4.1M | +178,720 |
| Geode Capital Management, LLC | 3,789,948 | $4.1M | +1,544,598 |
| State Street Corp. | 2,437,337 | $2.6M | +882,756 |
| First Manhattan Co. LLC. | 2,188,550 | $2.3M | +1,865,100 |
| Wells Fargo & Company | 2,067,046 | $2.2M | +792,656 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B